Skip to Content

Fully synthetic nano-antibodies · 100% animal-free

Theantibodyrevolutionstarts now.

We develop fully synthetic nano-antibodies (VHH): without a single laboratory animal, with unmatched precision and in weeks instead of months.

For 500 million years, only vertebrates could produce fully functional antibodies. We have fundamentally changed that.

The problem

Antibody development is slow, expensive and ethically problematic.

Conventional, animal-based methods have become the bottleneck of pharmaceutical research, with four shortcomings that cause massive sunk costs every year.

  1. 01

    Millions of laboratory animals

    Current methods rely on animal immunization or animal-derived libraries, using and losing millions of animals per year and raising considerable ethical and regulatory concerns.

  2. 02

    Blind spots caused by homology

    Immune tolerance in animal systems prevents robust responses against highly conserved human proteins, including crucial cancer markers. It is precisely the most important targets that remain inaccessible.

  3. 03

    Too slow when it counts

    Conventional antibody generation typically takes 6 to 12 months, which makes it unsuitable for time-critical scenarios such as pandemics or rapidly progressing diseases.

  4. 04

    Expensive and unpredictable

    Animal-based workflows are costly, resource-hungry and uncertain: low screening efficiency and limited reproducibility lead to high development risk.

The technology

Fully synthetic libraries, made easy to understand.

Instead of bulky classical IgGs, we develop nano-antibodies: 10x smaller, extremely stable, deeply tissue-penetrating and modular. Our platform combines unlimited synthetic diversity with the functionality of the vertebrate immune system, recreated in bacteria.

Pillar 01

Nano-antibodies

Stability, tissue penetration and low immunogenicity for multifunctional applications.

Pillar 02

Homology

Synthetic libraries bypass immunological blind spots: new specificities become accessible.

Pillar 03

Functionality

Functional selection yields up to 100% functional clones, unmatched by competitors.

Pillar 04

Scalability

Built on standard biotechnology: extreme selection pressures, industrial scale-up.

1

Synthetic diversity

Unlimited library

Fully synthetic, randomized gene libraries generate exceptional diversity: sequence polymorphisms and targeted length variations across the CDR1–CDR3 regions. This massively expands the accessible binding space.

2

Functional selection

B cell maturation in bacteria

A bacterial recreation of B cell maturation enriches exclusively correctly folded, functional nano-antibodies. Dysfunctional clones (up to 80% in classical libraries) are systematically eliminated early on.

3

SporoBead display

Robust selection on spores

Selection takes place on bacterial endospores: stable genotype-phenotype coupling even under the harshest washing conditions, giving full access to the diversity without the losses of classical display technologies.

// Animal testing

0%

Laboratory animals: completely animal-free development

// Screening

80%

less screening effort, faster from hit to lead

// Clones

100%

functional clones, the full potential of every library

// Diversity

20000000

* infinite antibody universe: access to novel targets …

Your benefit

Measurable advantages for your projects.

The combination of a fully synthetic library, functional selection and SporoBead display delivers technological, economic and regulatory advantages.

Efficiency01

80 %

Reduced screening effort

A highly selective candidate pool reduces laboratory screening by up to 80%, and the phage display bottleneck is eliminated.

Speed02

Faster time to lead

Fewer iterations, faster from hit to validated lead: weeks instead of months.

Success rate03

Higher probability of success

Unstable or non-functional variants are eliminated early. What remains, binds.

VHH advantage04

10×

Structural superiority

10x smaller than IgGs: higher binding density and extreme thermal and chemical stability.

Reach05

Access to difficult targets

Binders against conserved or structurally challenging epitopes, previously out of reach.

Precision06

Precise specificity design

Active control of cross-reactivities through combined positive and negative selection.

Robustness07

Predictable, robust processes

Fully synthetic and independent of immune responses or secretion systems: reproducible by design.

Quality08

≥99 %

Industrial feasibility

Validated purity ≥ 99%, high yields and immediate scalability.

YMOLUTION nano-antibodiesBESTBODIES

Applications · BESTBODIES

The next generation of antibody applications.

From research through in vitro diagnostics to therapy: our nano-antibodies open doors that remain closed to conventional antibodies.

Next-gen architecture

  • Ultra-compact: 10x smaller than IgGs, enabling tissue penetration & high binding density.
  • Blood-brain barrier: improved penetration for the treatment of CNS disorders.
  • Simple logistics: no cold chain required, lower costs, global distribution.

Unlocking the inaccessible

  • New human targets: animal-free selection bypasses immune tolerance (anergy).
  • Intracellular access: addresses proteins previously considered “undruggable”.
  • Proteome innovation: precision targeting of KRAS, TP53 and tau.

Personalized medicine

  • Precision diagnostics: high-affinity detection of patient-specific tumor markers.
  • Modular therapeutics: building blocks for bispecific antibodies & CAR T.
  • Unmatched velocity: from target to binder in under 4 weeks.

BSR HIA

2026

Winner
of the award

Awarded & validated

Trust built on evidence.

We have successfully validated our platform and produced the first high-affinity nano-antibodies with demonstrated functionality, confirmed by NIR Western blots and > 99% purity by mass spectrometry. Backed by a top-tier industry and research network.

Baltic Sea Region Health Innovation Award: awarded at the National Health Industry Conference in Rostock.

Winner 2026Rostock
  • Host institutionUniversity Medicine Greifswald
  • FundingEXIST-funded
  • SinceFounded in January 2026

Press & Awards

Awarded, noticed, talked about.

Awards for our research and selected voices from the press and academia: a look at what Ymolution is moving.

Pitch video

Hear it from the founders.

In just a few minutes, Managing Directors Dr. Alexander Reder and Dr. Christian Hentschker explain why the antibody revolution is not merely a vision but a necessity, and how three innovations are making it a reality.

  • The problem70% of commercially available antibodies do not work, or do not work as specified, with production times of 3–12 months.
  • The solutionThree innovations: a fully synthetic library, a functionality selection that is unique worldwide, and superior SporoBead panning.
  • The speedSpecific nano-antibodies in 2–3 weeks instead of months, in a clean freedom-to-operate situation.
PITCH · FOUNDERS

“We make the impossible accessible.”

The team

Science meets strategy.

A complementary founding team from science, business and operations, institutionally backed by University Medicine Greifswald as a shareholder.

The YMOLUTION founding team, group photo

Management

Dr. Alexander RederCo-CEO · Research & Product Development
Dr. Christian HentschkerCo-CEO · Organization & Research

Team

Jan MeieringBusiness
Marc SchafferTechnical Assistant
Tilly HoffmüllerResearch Assistant
Jette RossowResearch Assistant

The Antibody Revolution. Join us!

Do you have a challenging antigen? Send us your high-value targets. We will identify the perfect binders.

From 2027, fully validated production capacities will be available.From target to lead in weeks instead of months.

Contact

Let’s talk about your target.

Tell us what you need, whether a customer inquiry or a technology partnership. We will get back to you personally and promptly.

  • A personal reply from the founders
  • Initial feasibility assessment
  • Confidential, under NDA on request
  • Responsewithin 2 business days
  • AddressWalther-Rathenau-Str. 49b, 17489 Greifswald
  • Host institutionUniversity Medicine Greifswald · EXIST-funded
* Required fieldSend inquiry